Navigation Links
Medbox Acquires 50% of MedVend and its Patented Technologies
Date:3/15/2013

HOLLYWOOD, Calif., March 15, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) (www.medboxinc.com), a leader in providing industry specific consulting services and patented systems to the medical and retail industries worldwide, announced acquiring a 50% partnership stake in MedVend, LLC (www.medvendonline.com), a Michigan based bio-tech company that developed a patented automated medicine dispensing machine used for traditional prescription pharmaceutical dispensing. The deal involved cash and a restricted stock component totaling up to $5,150,000. The amount includes a $300,000 capital infusion and additional loans if needed for operating expenses into a jointly controlled new corporation (MedVend, Inc.) that will operate the business on a going forward basis. Besides infusion capital and other such loans, any equity payments included within the deal may be paid in cash or issuance of restricted MDBX common stock, at Medbox's sole discretion, after one year from execution.

MedVend's Automated Medication Dispenser (AMD) is a remote pharmacy that dispenses medication. Each AMD is located in convenient locations such as the lobby of a physician's office, urgent-cares, hospitals and pharmacies. The AMD uses state-of-the-art video and e-scripting technologies to provide patients with remote, face-to-face consultation with a pharmacist and to have their prescription medications filled in less than one minute. A patient simply touches the display monitor, enters their date of birth and a unique four-digit code issued to them at the point of care. The AMD provides the patient with their bottled medication interaction report, prescription and receipt all in less than one minute. If a patient has questions regarding their medication they can simply pick up the phone located on the AMD and they will be immediately connected with the pharmacist who appears on screen via two-way video conferencing.

The company has exclusive rights to Patent Number US7689318, an asset now jointly owned by Medbox. A summary of the patent is as follows:

"An inventory control and prescription management and dispensing system including a dispensing vault for storing and dispensing prescriptions in communication with a central computer system which communicates with prescription providers, insurance companies and other third parties. The vault includes robotic means for dispensing pre-filled prescriptions with the aid of RFIDs, barcodes or other means for verifying the medication to be dispensed. The vault uses patient biometrics, a patient registration system, insurance information and doctor information to process the transaction and dispense a specifically labeled pre-filled prescription to the patient."

Medvend enjoys many different revenue streams and benefits, as listed below:

MedVend has 5 main revenue streams:

  1. Sale of fully Automated Medication Dispensing Systems
  2. Sale of Medication
  3. Flat Management fee per dispensed Rx
  4. Marketing Programs on Automated Medication Dispensing Systems
  5. Monetizing anonymous data points through sale of data to Pharmaceutical R & D and marketing companies

Benefits to Medical center, Physician office, Urgent cares, and ER's:

  1. Profit Center for Healthcare facility
  2. Unparalleled convenience to Patients for competitive edge
  3. 100% write off under Tax rule 179 and Tax Code 44
  4. Assist practice in meeting their meaningful use requirement
  5. Assist the Hospital in reducing the attrition rate of patients coming back from standard nursing facilities (SNF's) by obtaining their meds prior to leaving the hospital.

Patient Benefits:

  1. Unparalleled convenience
  2. Competitive Rx cost
  3. Addressing their ailment at the point of care
  4. A higher quality assurance through automation on the prescription fulfillment

The company has already passed beta testing and currently has several machines in the field and is currently working with several large hospital groups to bring this unparalleled level of convenience to patients across the country by the end of 2013.  

"MedVend adds a piece of the puzzle that Medbox was missing in the traditional medicine dispensing sector. The ability to label medications, video conference with pharmacists, have video confirmations in real-time as to the exact medication dispensed and to whom, is truly the future of convenience and accuracy in a traditional pharmaceutical setting," stated Dr. Bruce Bedrick , CEO of Medbox, Inc. "We were fortunate to add MedVend and its valuable patent to our ever expanding portfolio of patents and companies. MedVend needed expansion capital and Medbox answered their request. Now we are a team."  

About Medbox, Inc: 

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Arizona, Connecticut, Massachusetts, Tokyo, London and Toronto, and has their corporate headquarters in Los Angeles.

Medbox provides their patented systems, software and consulting services to pharmacies, dispensaries, urgent care centers, drug rehab clinics, hospitals, prison systems, hospice facilities, and medical groups worldwide.

Medbox, Inc. is a publicly traded company, and is quoted on the OTC Markets, ticker symbol MDBX.

For more information on Medbox, please contact the Medbox Investor Relations Department at (800) 762-1452 or go online to www.medboxinc.com.

Forward-Looking Statements: The statements in this press release regarding state adoption of technology similar to that offered by Medbox and MedVend constitute forward-looking statements within the meaning of federal securities laws.  Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control.  In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change.  Potential risks and uncertainties include, but are not limited to, technical advances in the industry, political conditions and economic conditions in the states considering such legislation.  We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.


'/>"/>
SOURCE Medbox, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medbox CEO Scheduled to Appear on Fox Business Channel
2. Medbox Signs Ad Deal With Entrepreneur Magazine
3. Medbox Featured in Huffington Post Report on the Legal Marijuana Industry
4. Medbox, Inc. Sees Opportunity in Several New States
5. Medbox, Inc. Comments on California Supreme Court Decision
6. Medbox, Inc. Unveils Customer Financing Program
7. Medbox, Inc. Finalizes Manufacturing Plans for 2013 Product Line
8. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
9. Medbox, Inc. Commences Pursuit of Strategic Acquisitions
10. Medbox, Inc. Offers Guidance and Consultation To Washington State
11. Medbox Updates Financial Projections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... specializing in medical device compliance and commercialization, has just released a new ... , FDA is more adamant than ever about medical device, pharmaceutical, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The Garland ... a redesigned website. The new site – still located at http://www.garlandco.com ... and other industry users that Garland serves. , After an ambitious phase of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of ... life. This mouse sets out on a journey that will show that friends are ... creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s ...
Breaking Medicine News(10 mins):